for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aspen Pharmacare Holdings Limited

APNJ.J

Latest Trade

9,403.00ZAc

Change

-197.00(-2.05%)

Volume

4,377,069

Today's Range

9,314.00

 - 

9,744.00

52 Week Range

6,407.00

 - 

19,300.00

As of on the Johannesburg Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
9,600.00
Open
9,600.00
Volume
4,377,069
3M AVG Volume
38.87
Today's High
9,744.00
Today's Low
9,314.00
52 Week High
19,300.00
52 Week Low
6,407.00
Shares Out (MIL)
455.97
Market Cap (MIL)
43,819.35
Forward P/E
6.50
Dividend (Yield %)
--

Next Event

Aspen Pharmacare Holdings Ltd Annual Shareholders Meeting

Latest Developments

More

Aspen Pharmacare Posts FY Normalised HEPS From Cont Ops Down 7%

Aspen Pharmacare Intends Releasing Results For FY On Sept 11

Aspen Pharmacare Sees FY Total HEPS 1,224-1 283 Cents

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aspen Pharmacare Holdings Limited

Aspen Pharmacare Holdings Limited is a South Africa-based supplier and manufacturer of branded and generic pharmaceutical products, as well as infant nutritional and consumer healthcare products. The Company's segments include International, South Africa, Asia Pacific and Sub-Saharan Africa (SSA). Its International business includes operating subsidiaries in Europe, Commonwealth of Independent States (CIS), Latin America, the Middle East and North Africa, Canada, as well as Mauritius-based Aspen Global Incorporated. The South African business provides branded, generic, over-the-counter, consumer health and infant nutritional products, which are supplied to pharmacies, retail pharmacy chains, hospitals, clinics, prescribing specialists, dispensing general practitioners, managed healthcare funders and retail stores across the private and public sectors in South Africa. Its business in Asia Pacific includes operations in Australasia, the Philippines, Taiwan and Japan.

Industry

Biotechnology & Drugs

Contact Info

Woodmead

+27.31.5808600

http://www.aspenpharma.com/

Executive Leadership

Kuseni Douglas Dlamini

Non-Executive Chairman of the Board

Stephen Bradley Saad

Group Chief Executive, Executive Director

Michael Guy Attridge

Deputy Group Chief Executive, Executive Director

Riaan Verster

Company Secretary and Group Governance Officer

Roy Cecil Andersen

Lead Independent Non-Executive Director

Key Stats

2.00 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, ZAR)

2017

41.2K

2018

42.6K

2019

38.9K

2020(E)

40.7K
EPS (ZAR)

2017

13.000

2018

16.050

2019

14.143

2020(E)

14.777
Price To Earnings (TTM)
16.14
Price To Sales (TTM)
1.13
Price To Book (MRQ)
0.80
Price To Cash Flow (TTM)
11.21
Total Debt To Equity (MRQ)
87.32
LT Debt To Equity (MRQ)
72.31
Return on Investment (TTM)
2.63
Return on Equity (TTM)
2.13

Latest News

Aspen's drug to prevent preterm birth approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Aspen Pharmacare's hydroxyprogesterone caproate (HPC), which is used to prevent preterm birth in pregnant women, the South African drugmaker's CEO said on Thursday.

UPDATE 2-Aspen posts lower FY profit on weaker manufacturing results, no dividend

* Intends to restart heparin supply to third-parties (Adds details)

South Africa's Aspen posts FY earnings decline, pays no dividend

South African drugmaker Aspen Pharmacare Holdings said on Wednesday full-year normalised earnings fell by 7% and it would not pay a dividend this year.

South African drugmaker Aspen lowers debt, shares jump

Aspen Pharmacare Holdings Ltd <APNJ.J> said on Tuesday its debt as of June 30 had fallen below 40 billion rand ($2.63 billion) and that levels were safely below a covenant threshold, sending shares in the South African drugmaker up more than 9%.

South Africa's Aspen to pay 8 million pounds to NHS after UK probe

British authorities said on Wednesday South Africa's Aspen Pharmacare Holdings Ltd <APNJ.J> has agreed to pay the National Health Service (NHS) 8 million pounds to resolve concerns related to overpayment for a treatment.

South Africa's Aspen to pay 8 mln pounds to NHS after UK probe

British authorities said on Wednesday South Africa's Aspen Pharmacare Holdings Ltd has agreed to pay the National Health Service (NHS) 8 million pounds ($9.65 million) to resolve competition concerns related to a company's treatment.

South African drugmaker Aspen terminates talks with potential European partner

South African drugmaker Aspen Pharmacare said on Friday it had terminated talks with a potential partner in Europe, after announcing in March a strategic review of its European and domestic commercial pharmaceuticals businesses.

South Africa's Aspen sells Australian prescription portfolio to Mylan

Aspen Pharmacare said on Monday that Mylan NV had exercised an option to buy the South African drugmaker's portfolio of prescription and over-the-counter products in Australia for 188 million Australian dollars ($130 million).

South Africa's Aspen sells Australian prescription portfolio to Mylan

Aspen Pharmacare said on Monday that Mylan NV had exercised an option to buy Aspen's portfolio of prescription and over-the-counter products in Australia for 188 million Australian dollars ($130 million).

UPDATE 1-South Africa's rand recovers after U.S. jobs data, stocks slide on Aspen

South Africa's rand firmed on Friday, recovering from a nine-week low after sluggish U.S. employment data pushed the dollar lower and saw demand for emerging markets return.

UPDATE 2-Shares in S.Africa's Aspen plunge on debt, slow sale proceeds

* Debt levels still within creditor threshold (Adds historical debt, details)

Aspen shares plunged by nearly 40 pct on debt worries

Shares of South Africa-based drugmaker Aspen Pharmacare plunged nearly 40 percent on Friday, as rising debt worried investors.

UPDATE 1-Aspen to split South African pharma business after disposal of non-core assets

Multinational drugmaker Aspen Pharmacare said it will split its South African Commercial Pharmaceuticals business into two divisions as it disposes of non-core assets to reduce its debt.

UPDATE 1-Aspen Pharmacare drops on debt worries and revenue forecast

Shares in Aspen Pharmacare fell more than 8 percent on Friday, a day after the South African drugmaker said it had negotiated a temporary relaxation of its lending agreements and forecast little growth in full-year revenues.

South Africa's Aspen strikes distribution deal with U.S. drugmaker Mylan

Aspen Pharmacare has struck a deal with U.S. generics maker Mylan to distribute a portfolio of prescription and over-the-counter drugs in Australia and New Zealand.

South Africa's Aspen launches three-in-one HIV drug

South African drugmaker Aspen Pharmacare on Monday launched a triple-combination tablet for the treatment of HIV in the country where the virus is most prevalent.

South Africa’s Aspen to invest $231 million in sterile anaesthetics manufacturing

South African drug maker Aspen Pharmacare will invest an additional 3.4 billion rand ($231 million) at its Port Elizabeth plant, it said on Friday at an investment summit in Johannesburg.

Aspen Pharma suffers week of woe as valuation tumbles by $3 bln

* Investors spooked by debt levels and sale of baby milk business

Drugmaker Aspen sells baby milk business to dairy giant Lactalis

Aspen Pharmacare <APNJ.J> has agreed to sell its infant formula business to Lactalis for 12.9 billion rand (660.64 million pounds) to focus on core activities while the French buyer looks to revive its baby milk expansion after a health scandal.

Lactalis says Aspen deal to boost overseas business

Privately held French dairy group Lactalis said on Thursday its takeover of Aspen's <APNJ.J> global infant formula business would boost its presence in Latin America, Africa, Australia and Asia.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up